Overview

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

This study will evaluate safety and efficacy of TKI258 in patients with relapsed or refractory multiple myeloma

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals